About this case
In April 2020 the FDA asked manufacturers to pull ranitidine (Zantac) from the market after finding unacceptable levels of NDMA, a probable carcinogen. Lawsuits claim long-term use led to certain cancers.
Where the case stands
This litigation has had major setbacks: the federal cases were dismissed (an appeal is pending) and a Delaware court dismissed tens of thousands of state cases in April 2026, while GSK and other manufacturers settled many claims. Intake is limited, so a reviewer will confirm whether your claim can still be pursued.
Status last reviewed November 2026. Lawsuit developments change often.
Who may qualify
- You took Zantac or generic ranitidine regularly (generally at least weekly for a year)
- You were later diagnosed with a qualifying cancer
- Your claim is within your state's filing deadline
Injuries and conditions involved
Free · Confidential · About 2 minutes
Find out if you qualify
Answer a few quick questions about your Zantac claim. There's no cost and no obligation.
See If I QualifyPrefer to talk? Call (877) 342-6154


